Tesaro, Inc.

Company type	Subsidiary
Industry	Pharmaceuticals
Founded	2010; 14 years ago (2010), in Waltham, Massachusetts
Headquarters	Waltham  , United States
Products	Varubi
Number of employees	286 (2016)
Parent	GSK (2019–present)
Website	tesarobio.com

Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.

History

Tesaro was founded in 2010.^[1] The company's first commercial product, Varubi, was approved by the FDA in October 2015.^[2] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.^[3] The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA.^[4] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.^[5] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.^[5] On December 3, 2018, GSK announced it would acquire the company for $5.1 billion,^[6] and the deal was completed on January 22, 2019.^[7]

Products under development

• Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
• Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.^[8]
• TSR-042
• TSR-022
• Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.